-+ 0.00%
-+ 0.00%
-+ 0.00%

Changes in US stocks | Bambusa Therapeutics (BBTX.US) enters the US stock market, and the stock price falls by more than 8%

Zhitongcaijing·10/30/2026 16:17:15
Listen to the news

The Zhitong Finance App learned that on Friday, Bambusa Therapeutics (BBTX.US) entered the US stock market. As of press release, the stock had fallen more than 8% to $14.685. The IPO price is $16. Bambusa Therapeutics is a clinical-stage biopharmaceutical company headquartered in Boston, USA, focused on developing a new generation of long-lasting bispecific antibody drugs to treat immune system and inflammatory diseases. These drugs can simultaneously target two disease-related biological targets, and aim to improve treatment effectiveness, prolong the duration of efficacy, and reduce the frequency of drug use by patients. The company's main drug, BBT001, is used to treat skin diseases such as atopic dermatitis (eczema) and chronic spontaneous urticaria; another drug candidate, BBT002, mainly targets inflammatory diseases such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis with nasal polyps. Additionally, the company is developing early-stage medicines for inflammatory bowel disease and autoimmune diseases.